What was recalled
In a move to ensure the integrity of prescription medications available to patients across the United States, the U.S. Food and Drug Administration (FDA) has issued a recall involving specific batches of Lidocaine Ointment USP. This product is distributed under the joint branding of SUN PHARMA and TARO. The recall specifically targets the 5% strength formulation, which comes in a distinctive Speermint Flavor profile, packaged in 50-gram jars. It is important to note right away that this is a prescription-only medication, meaning it is not an over-the-counter item you would typically pick up off a shelf without a doctor’s order.
The product in question was manufactured by Taro Pharmaceuticals Inc., located in Brampton, Ontario, Canada (specifically at postal code L6T1C). Following manufacturing, the items were distributed to the U.S. market by Taro Pharmaceuticals U.S.A. Inc., based in Hawthorne, New York, 10532. If you are looking at your medicine cabinet or pharmacy receipt, you should check for the National Drug Code (NDC) number 51672-3008-5. This code is your primary identifier for this specific recall event.
Not all jars of this product are affected. The recall is limited to a single, specific lot number: AD48154. If your jar has a different lot number, it is not part of this safety action. Furthermore, the expiration date on the recalled items is April 30, 2027. This means the product was still within its labeled shelf life at the time of the recall announcement, which happened on August 31, 2026. The distribution pattern for these specific units was nationwide, covering all 50 states in the USA. Because it was distributed broadly, anyone who filled a prescription for this specific lidocaine ointment between the manufacturing date and the recall date in New York or elsewhere in the country may have one of these jars.
Why is this specific product being pulled from shelves? The core issue lies in quality control standards during stability testing. During analysis at the 24-month long-term stability station—conducted under conditions of 25 degrees Celsius and 60% relative humidity—the product failed content uniformity specifications. Additionally, it was found to be out of specification for assay. In plain terms, this means that the amount of active drug ingredient (lidocaine) in the ointment did not meet the strict standards required for consistency and potency. While the recall classification is Class II, indicating that use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, it is still a significant quality failure that warrants immediate attention.
If you have this medication, do not panic, but do act. Check your jar immediately for the NDC 51672-3008-5 and Lot # AD48154. If these match, stop using the product and contact your pharmacist or healthcare provider for instructions on how to return or dispose of it safely. The remedy for this specific recall has not yet been explicitly stated in the initial FDA record, so following up with your pharmacy is the most prudent next step.
The hazard, explained
At first glance, a pharmaceutical recall due to "Failed Content Uniformity Specifications" might sound like a minor bureaucratic hiccup rather than a serious safety threat. However, in the world of medicine, consistency is not just about quality control; it is the very foundation of patient safety. For Lidocaine Ointment USP, 5%, this specific failure means that the amount of active drug—lidocaine, the numbing agent—inside each portion of the ointment is unpredictable and inconsistent. The recall notice from the FDA indicates that the product failed an assay analysis at the 24-month long-term stability station, held at standard storage conditions of 25°C and 60% relative humidity. This tells us that over time, as the jar sits on a shelf or in a medicine cabinet, the chemical composition has shifted in a way that violates strict government standards for uniformity.
To understand why this is dangerous, it helps to look at how lidocaine works. As a local anesthetic, lidocaine functions by blocking nerve signals in a specific area of the body. The "5%" concentration listed on the label is not arbitrary; it is a carefully calibrated dose designed to provide effective pain relief without causing systemic toxicity or excessive tissue irritation. When content uniformity fails, you can no longer trust that every gram of ointment contains exactly 5% lidocaine. Instead, you might be applying an area with significantly less drug, rendering the treatment ineffective and allowing pain or discomfort to persist unmanaged. Conversely, and more dangerously, other parts of the same jar may contain higher-than-intended concentrations of the active ingredient.
The risk of overdosing is particularly acute with topical anesthetics like lidocaine. When too much lidocaine is absorbed through the skin into the bloodstream, it can lead to serious systemic effects known as Local Anesthetic Systemic Toxicity (LAST). While rare in normal use, applying a product with unexpectedly high drug content increases this risk. Symptoms of lidocaine toxicity can range from mild dizziness and nausea to more severe neurological issues such as seizures, heart rhythm disturbances, or respiratory depression. Because the failure was detected during stability testing, it suggests that the inconsistency worsens over time. A jar that appears normal when first opened might become increasingly unreliable as it approaches its expiration date, making the final weeks of use particularly hazardous.
Furthermore, this defect undermines the trust patients place in prescription medications. When a drug is labeled "Rx only," it implies a high degree of reliability and professional oversight. A failure in assay uniformity means that the manufacturing or storage processes did not maintain the integrity of the product as intended. For consumers relying on this ointment for post-surgical pain, dental procedures, or chronic skin conditions, receiving an inconsistent dose can lead to improper wound care, delayed healing, or unnecessary exposure to adverse drug reactions. The FDA classifies this as a Class II recall, indicating that while the products are not likely to cause serious health consequences for most users, the potential for temporary or medically significant problems exists if the inconsistency leads to under-dosing (treatment failure) or, in sensitive individuals, over-exposure.
Who is most at risk
When we talk about who is "at risk" in a drug recall like this one, it is important to distinguish between two very different kinds of danger. This specific recall by Sun Pharma and Taro Pharmaceuticals involves Lidocaine Ointment USP, 5%, which failed content uniformity specifications during stability testing. Because the issue is manufacturing consistency rather than immediate toxicity or contamination, the primary risk is not sudden poisoning for the general population. Instead, the risk lies in the unpredictability of the medication’s effect. This affects anyone who relies on this prescription to manage pain, but it poses a particular challenge for patients who require precise dosing to maintain their quality of life.
The product in question is classified as Rx only, meaning it is available exclusively by prescription. Therefore, the group most directly impacted consists of individuals who have been prescribed this specific 5% Lidocaine ointment for conditions such as neuropathic pain, localized nerve pain, or other dermatological discomforts managed with topical anesthetics. For these patients, the "risk" is therapeutic failure. If the content uniformity is off, one application might deliver too little lidocaine to be effective, leaving the patient in pain, while another application from the same jar might deliver a higher dose than intended. This unpredictability can lead to frustration, untreated symptoms, or unintended side effects if the user compensates by applying more of the product.
While the recall does not single out a specific demographic like children or the elderly for unique biological vulnerability in this context, certain patient populations may feel the impact of this inconsistency more acutely. Elderly patients, who often manage multiple chronic conditions and take various medications, rely heavily on consistent pain management to maintain mobility and independence. A failure in pain control can lead to reduced physical activity, which has its own serious health implications for older adults. Similarly, individuals with sensitive skin or those using the ointment over large surface areas may be more susceptible to systemic absorption issues if the actual concentration of lidocaine varies significantly from the labeled 5%. Although the recall notice does not report any injuries or adverse events, the potential for variable dosing remains a concern for anyone depending on this medication for daily comfort and function.
It is also worth noting that because the distribution pattern was nationwide, no geographic region is exempt from this uncertainty. However, the specific lot number AD48154 with an expiration date of April 30, 2027, is the only batch identified in this action. If you are not currently using this exact product from Sun Pharma/Taro, your risk from this specific recall is zero. The vulnerability here is tied directly to possession and use of the recalled item, rather than a broad public health threat. Patients who have been prescribed generic lidocaine ointment by other manufacturers or in different strengths are not at risk from this particular event.
How to tell if you have the recalled item
Before taking any action, it is absolutely critical that you verify whether your specific product falls within this recall. Because recalls often target very precise batches rather than entire product lines by default, checking the identifying details on your packaging is the only way to be certain. Please do not rely solely on the brand name or the general type of medication, as other lots from the same manufacturer may be safe and unaffected.
First, locate the box or container holding your Lidocaine Ointment USP. You are looking for a 50-gram jar with a Speermint Flavor. The label should clearly state that it is Rx only (prescription) strength. Look closely at the manufacturer information printed on the packaging. It must identify the product as manufactured by Taro Pharmaceuticals Inc., located in Brampton, Ontario, Canada, and distributed by Taro Pharmaceuticals U.S.A. Inc. in Hawthorne, New York. If your jar lists a different distributor or manufacturer address, it is not part of this specific recall notice.
The most important details to check are the National Drug Code (NDC) and the Lot Number. These unique identifiers act like a fingerprint for that specific batch of medication. On your box or jar, find the NDC number. The recalled item carries the code 51672-3008-5. Next, locate the Lot number, which is often printed near the expiration date. For this recall, you are looking specifically for Lot # AD48154. If your lot number differs from AD48154, even if the NDC matches, it is likely not included in this specific safety alert.
You should also check the expiration date to ensure you have the correct version of the product. The recalled jars have an expiration date of April 30, 2027. While the expiration date alone does not confirm a recall, it helps narrow down the timeframe of production. This recall applies to products distributed nationwide in the USA, so where you purchased it does not matter, but the physical details on the label do. If your product matches all these criteria—the specific NDC, Lot # AD48154, and expiration date—you have the recalled item. In this case, stop using it immediately and follow the remedy instructions provided by the FDA.
If you are unsure or cannot find these details on the original packaging, contact the distributor listed above with your product information. Do not guess. It is better to be certain than to risk using a product that may have failed content uniformity specifications during stability testing. This verification step protects you from unnecessary worry while ensuring you take action only if truly needed.
What to do — step by step
If you currently possess a jar of the recalled SUN PHARMA / TARO Lidocaine Ointment USP, 5%, Speermint Flavor (50 g Jar), your immediate priority is to ensure that no further doses are administered. Although the specific remedy details were not explicitly stated in the official FDA recall announcement for this Class II event, standard safety protocol for pharmaceutical products failing content uniformity or assay specifications dictates that you must stop using the product immediately. The risk here is not necessarily that the ointment is toxic, but rather that the dosage may be inconsistent. If the active ingredient (lidocaine) is present in amounts lower than labeled, you might receive inadequate pain relief, leading you to apply more product and potentially exceed safe limits. Conversely, if the concentration is higher than expected, you risk systemic absorption issues. Therefore, treating the product as unusable is the only safe path forward.
First, locate the specific jar in your home. You are looking for a 50-gram container with a spearmint flavor. To confirm it is part of this recall, you must check two critical identifiers on the packaging: the National Drug Code (NDC) and the Lot Number. This specific recall applies only to NDC 51672-3008-5 and Lot # AD48154, which has an expiration date of April 30, 2027. If your jar does not match these exact numbers, it is not part of this batch and you may continue to use it as directed by your healthcare provider. However, if it matches, do not attempt to dispose of the medication in your household trash or down the drain, as this can pose environmental or accidental ingestion risks.
Next, contact the manufacturer or distributor for further instructions on how to return or discard the product. The product was distributed by Taro Pharmaceuticals U.S.A. Inc., located in Hawthorne, NY. While the recall facts do not provide a direct phone number or email address for this specific action, you should visit the official FDA website or contact Taro Pharmaceuticals directly to inquire about their return process. They may offer prepaid shipping labels or specific drop-off locations. If you purchased this item from a pharmacy, call your local pharmacist immediately; they often have established protocols for handling recalled medications and can guide you through the return process or advise on how to safely dispose of it if a direct return is not available.
Finally, monitor yourself for any adverse effects if you used the product prior to discovering the recall. While lidocaine ointment is generally safe when used correctly, inconsistent dosing can lead to unexpected side effects such as skin irritation, dizziness, or heart rhythm changes in sensitive individuals. If you experience any unusual symptoms after using this specific lot, seek medical attention and inform your provider that you used a recalled product. Keep the packaging with you until you have confirmed its status and handled its disposal properly, as it contains the necessary information for healthcare professionals to assess your situation accurately.
Your refund, repair, or replacement options
When you receive notice that a medication has been recalled, the immediate question on your mind is often, "What happens to my money and my prescription?" In this specific case involving the recall of SUN PHARMA / TARO Lidocaine Ointment USP, 5%, Speermint Flavor, the official recall documentation provides a critical detail that many consumers might overlook: the remedy is not stated. It is completely understandable to feel uncertain or even slightly anxious when standard return instructions are missing from a public notice, but this absence of explicit instructions does not mean you are left without recourse. Instead, it means the process relies on established pharmaceutical distribution channels and direct communication with the responsible parties.
Because the official record does not list a specific refund portal, prepaid shipping label, or automated return address, the most reliable path forward is to contact the entities directly involved in the supply chain. The product was distributed by Taro Pharmaceuticals U.S.A. Inc., located in Hawthorne, New York, and manufactured by Taro Pharmaceuticals Inc. in Brampton, Ontario. These companies are legally obligated to manage the recall process, even if the public summary does not detail the exact mechanics of the refund or replacement. Your first step should be to reach out to your healthcare provider or the pharmacy where you filled the prescription. Pharmacists have direct lines to manufacturer representatives and can often provide immediate guidance on whether a partial or full refund is being processed automatically by the pharmacy’s accounting system.
If you purchased this item directly from a retailer or online platform, do not attempt to return it through standard customer service channels without confirmation. Medications that have failed content uniformity specifications are considered unsafe for use and must be handled as potentially hazardous waste. Returning them to a general retail drop-off bin could pose risks to others. Instead, contact the specific pharmacy or vendor where the transaction occurred and explicitly state that you hold Lot # AD48154 of the recalled Lidocaine Ointment. They will likely instruct you to either destroy the product safely at home (following their specific disposal guidelines) or bring it to a designated hazardous waste collection site, depending on local regulations.
Regarding compensation, while a direct refund mechanism is not published in this recall notice, you are generally entitled to reimbursement for the cost of the medication if it was prescribed and dispensed. If you have already paid out-of-pocket, keep your receipt and proof of purchase. Contact Taro Pharmaceuticals U.S.A. Inc. directly via their corporate customer service lines (which you can find on their official website or through your pharmacy) to inquire about financial restitution. They may issue a check or credit directly to the original point of sale, which then credits your account. Do not discard the product until you have received clear written or verbal confirmation from either your pharmacist or the manufacturer regarding the next steps for both safety and reimbursement.
In summary, while the "remedy" column in this recall report is blank, your options remain clear: prioritize safety by stopping use immediately, then leverage your pharmacy as your primary advocate. They will coordinate with Taro Pharmaceuticals to determine if a replacement prescription of a verified safe lot can be issued or if a financial refund is the appropriate resolution for your specific situation.
What can happen if you ignore it
When a pharmaceutical product fails to meet its specifications, the immediate reaction might be to shrug it off, especially if the item is sitting in your medicine cabinet unused or if you have already finished the tube. However, with medications like Lidocaine Ointment USP, which is designed to deliver a precise dose of an active ingredient to numb pain or itching, consistency is not just a regulatory formality—it is a matter of physiological safety and treatment efficacy. Ignoring this recall by continuing to use the affected lot, or by using other batches from the same distribution run before they are pulled from shelves, introduces unnecessary and unquantifiable risks to your health.
The specific hazard identified in this recall is a failure in Content Uniformity Specifications and an out-of-specification assay during long-term stability testing. In plain terms, this means that the amount of lidocaine in the ointment may not be what it claims to be on the label. This lack of uniformity can manifest in two dangerous ways: the concentration could be too low, or it could be unpredictably high. If the assay results indicate that the product does not meet the required standards for potency at the 24-month mark, it suggests a degradation process or a manufacturing inconsistency that compromises the drug’s reliability. You cannot know which jar you have by looking at it; the ointment may look, smell, and feel exactly like a safe, compliant product.
If the concentration is lower than stated, the primary consequence is treatment failure. Lidocaine is often prescribed for specific, manageable conditions where consistent relief is necessary. Using a product that delivers less active ingredient than expected means you are not getting the therapeutic benefit you were prescribed. This can lead to persistent pain or discomfort, potentially causing you to apply more of the ointment in an attempt to achieve relief. This behavior creates a secondary risk: by applying larger quantities to compensate for the perceived lack of potency, you may inadvertently expose your skin to other inactive ingredients or preservatives at higher-than-intended levels, or simply delay effective treatment for an underlying condition.
Conversely, and perhaps more seriously, if the content uniformity failure results in pockets of higher potency within the jar, the risk shifts from ineffectiveness to potential toxicity. Lidocaine is a local anesthetic that works by blocking nerve signals. While it is generally safe when used topically as directed, systemic absorption can occur, particularly if applied to broken skin or large areas of the body. An inconsistent product means that one application might be weak, while the next application from the same jar could deliver a significantly higher dose. This unpredictability makes it impossible to monitor your body’s response accurately. In rare cases, excessive systemic absorption of lidocaine can lead to serious adverse effects, including dizziness, heart rhythm disturbances, or central nervous system issues. Because this is an Rx-only medication, you are likely under the care of a professional who calculated a safe dosage based on a reliable product. Using a compromised product breaks that safety calculation.
Furthermore, ignoring the recall delays your access to a verified, safe alternative. The remedy for this specific issue is not explicitly stated in the current recall facts, which often implies that the manufacturer may be issuing a replacement or a refund rather than a complex repair process. By continuing to use the product, you are prolonging your exposure to an unverified variable in your healthcare routine. The FDA classifies this as a Class II recall, indicating that use of or exposure to the product might cause temporary health problems or pose a slight threat of a serious nature. This classification is not trivial; it is a signal that while immediate catastrophe is not guaranteed for every user, the risk is significant enough to warrant urgent action. The safest path is to stop using the product immediately, dispose of it properly, and consult your healthcare provider for a replacement from a verified, compliant batch.